TargetMol

20S Proteasome activator 1

Product Code:
 
TAR-T63321
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T63321-5mg5mg£122.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T63321-10mg10mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T63321-25mg25mg£225.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T63321-50mg50mg£334.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T63321-100mg100mg£503.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
20S Proteasome activator 1 is a 20S proteasome activator with IC50 of 0.3 uM for trypsin-like sites, 0.7 uM for chymotrypsin-like sites and 1.8 uM for caspase sites. 20S Proteasome activator 1 prevents the accumulation of pathogenic alpha-synuclein A53T mutants through translation in the cellular system, thereby reducing the probability of disease occurrence. The 20S Proteasome activator 1 can be used to study neurodegenerative diseases.
CAS:
2761578-18-9
Molecular Weight:
492.97
Pathway:
Ubiquitination|Proteases/Proteasome
Purity:
0.98
SMILES:
O=C(N(C1=CC=C(F)C=C1)C2=CC=C(F)C=C2)CCN3C=4C=CC=CC4SC5=CC=C(Cl)C=C53
Target:
Proteasome

References

Staerz SD, et al. Design, Synthesis, and Biological Evaluation of Potent 20S Proteasome Activators for the Potential Treatment of ?-Synucleinopathies. J Med Chem. 2022 May 12;65(9):6631-6642.